Hayden’s fifth venture, neuro-focused Prilenia, raises $62.5M in Forbion-led A round
The Dutch and Israeli company plans to take pridopidine into pivotal studies for Huntington’s, ALS
Serial entrepreneur Michael Hayden is taking the helm as CEO of Prilenia as it readies for a pair of studies next half that could show whether pridopidine can slow progression of neurodegenerative diseases more effectively than approved therapies.
The biotech raised $62.5 million in a Forbion-led series A on Wednesday, which will fund a Phase III trial in Huntington’s disease and a Phase IIb platform trial in amyotrophic lateral sclerosis.
Neither of the drugs approved for HD have an effect on functional capacity,